Our approach
Lean Discovery, Strong Partners, Experienced Leadership
We run a capital-efficient model: a small core team that sets strategy and makes decisions, working with specialist academic, computational and contract-research partners
Target selection
Picking validated targets
We prioritise mechanisms with strong biology, clear differentiation from existing antifungals and clean IP
Design
AI-enabled molecule design
Computational design with our partner Centella AI shortens the path from validated target to lead-like compounds
Translation
Plan the clinic early
Pharmacology, safety and regulatory strategy are planned from the start, so each program is built for the patients it will eventually serve